ReviewDrugs2008
Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.Journal of the International AIDS Society · 2014Pooled it
- Update on kidney transplantation in human immunodeficiency virus infected recipients.World journal of nephrology · 2016Review
- How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health.Health information science and systems · 2013Review
- In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.PloS one · 2013Article
- Robust closed-loop minimal sampling method for HIV therapy switching strategies.IEEE transactions on bio-medical engineering · 2012Article
- Antiretroviral drugs: critical issues and recent advances.Indian journal of pharmacology · 2012Article
- HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.PloS one · 2012Article
- Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.Journal of virology · 2011Article
- Controlling the Evolution of Resistance.Journal of process control · 2011Article
- Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.Antimicrobial agents and chemotherapy · 2010Article
- A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.Journal of virology · 2010Article
- Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching.Proceedings of the ... American Control Conference. American Control Conference · 2010Article
- Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region.Journal of antivirals & antiretrovirals · 2009Article
- Can an infectious disease genomics project predict and prevent the next pandemic?PLoS biology · 2009Article
- Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility.Journal of virology · 2009Article
- Viral resistance evolution fully escapes a rationally designed lethal inhibitor.Molecular biology and evolution · 2009Article
- Trapping moving targets with small molecules.Science (New York, N.Y.) · 2009Article
- Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.PLoS computational biology · 2009Article
- Pharmacologic aspects of new antiretroviral drugs.Current HIV/AIDS reports · 2009Review
- Trafficking through the Rev/RRE pathway is essential for efficient inhibition of human immunodeficiency virus type 1 by an antisense RNA derived from the envelope gene.Journal of virology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the second decade of highly active antiretroviral therapy, drug regimens offer more potent, less toxic and more durable choices. However, strategies addressing convenient sequential use of active antiretroviral combinations are rarely presented in the literature. Studies have seldom directly addressed this issue, despite it being a matter of daily use in clinical practice. This is, in part, because of the complexity of HIV-1 resistance information as well as the complexity of designing these types of studies. Nevertheless, several principles can effectively assist the planning of antiretroviral drug sequencing. The introduction of tenofovir disoproxil fumarate, abacavir and emtricitabine into current nucleoside backbone options, with each of them selecting for an individual pattern of resistance mutations, now permits sequencing in the context of previously popular thymidine analogues (zidovudine and stavudine). Similarly, newer ritonavir-boosted protease inhibitors could potentially be sequenced in a manner that uses the least cross-resistance prone protease inhibitor at the start of therapy, while leaving the most cross-resistance prone drugs for later, as long as there is rationale to employ such a compound because of its utility against commonly observed drug-resistant forms of HIV-1.
Indexed as
Identifiers
18081372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.